Open AccessS160: MOLECULAR DETERMINANTS OF DISEASE PROGRESSION AFTER HYPOMETHYLATING AGENT THERAPY IN RAS PATHWAY MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA AT THE SINGLE‐CELL LEVEL
Author(s) -
MontalbanBravo G.,
Ma F.,
GananGomez I.,
KanagalShamana R.,
Adema V.,
Thongon N.,
Yang H.,
Soltysiak K. A.,
BuesoRamos C.,
Kantarjian H.,
GarciaManero G.,
Colla S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843532.08926.df
Subject(s) - chronic myelomonocytic leukemia , cancer research , haematopoiesis , progenitor cell , myeloid leukemia , biology , leukemia , myeloid , hypomethylating agent , downregulation and upregulation , stem cell , immunology , bone marrow , gene , myelodysplastic syndromes , gene expression , genetics , dna methylation